Successful Anakinra Therapy in 2 Patients with Schnitzler Syndrome

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

SZTURZ Petr ADAM Zdeněk HÁJEK Roman MAYER Jiří

Year of publication 2011
Type Article in Periodical
Magazine / Source Onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Web http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=327816&Ausgabe=255308&ProduktNr=224106&filename=327816.pdf
Doi http://dx.doi.org/10.1159/000327816
Field Oncology and hematology
Keywords Schnitzler syndrome; Monoclonal gammopathy; Urticaria; Interleukin; Anakinra
Description Background: Schnitzler syndrome is a rare idiopathic disease characterized by chronic urticaria, presence of monoclonal IgM immunoglobulin, signs of inflammation and further symptoms. Often unrecognized, it may evolve into a lymphoproliferative disorder. Case Report: Two male patients presented pruritic and nonpruritic urticarias at the age of 45 and 43 years, respectively. Based on further symptoms (fever or subfebrile temperatures, bone and joint pains), laboratory tests (monoclonal IgM kappa, leukocytosis, elevated ESR and CRP) and radiological findings (osteolytic-osteosclerotic and hyperostotic skeletal changes), they were subsequently diagnosed with Schnitzler syndrome. Follow-up times were 15 years and 1 year, respectively. We monitored disease activity in the second patient, finding a correlation with CRP, ESR and interleukin IL-6 and IL-18 serum levels. As regards therapy, we used several medications (antihistamines, bisphosphonates, corticoids, 2-chlorodeoxyadenosine, interferon-alpha, cyclosporine, thalidomide, bortezomib) and PUVA treatment without achieving complete remission. Only anakinra (interleukin-1 receptor antagonist) minimized Schnitzler symptoms in both patients with very good drug tolerance. The first patient has been on anakinra monotherapy for 3 years (10/2007-10/2010) at a dosing interval of 24-48 hours without any signs of Schnitzler syndrome. Conclusions: Biological therapy using anakinra proved effective in Schnitzler syndrome, a rare entity with potentially life-threatening complications (malignancy, systemic amyloidosis).
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.